CLAIM CARD
The included studies span a diverse range of designs and populations examining the effects of SGLT2 inhibitors beyond primary glycemic control. This evidence base comprises several systematic reviews and meta-analyses (Balbaa 2026, Sayour 2024, Suciu 2025, Zhang 2023, Kumari 2026, Hung 2025) alongside multiple observational cohort studies (Cersosimo 2025, Loutati 2026, Park 2026, Andersson 2026, Duman 2025). Populations studied include adults with type 2 diabetes (Sayour 2024, Suciu 2025, Kumari 2026, Park 2026, Andersson 2026), adults with heart failure (Cersosimo 2025, Duman 2025, Loutati 2026), and frail or sarcopenic adults (Zhang 2023). The outcomes assessed are heterogeneous, encompassing cardiovascular events, endothelial function, renal parameters, body composition, dementia risk, echocardiographic measures, and cancer risk, as detailed in the evidence synthesis.
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025